Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α
- PMID: 22503752
- PMCID: PMC3378854
- DOI: 10.1016/j.ajpath.2012.03.006
Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α
Abstract
Numerous studies support the role for mutations in the phosphatase and tensin homologue (PTEN) tumor suppressor gene and unopposed estrogen stimulation in the pathogenesis of uterine endometrioid carcinoma. However, the relation between PTEN signaling and estrogen/estrogen receptor in endometrial tumorigenesis remains unresolved. We used genetically engineered mice as a model to address this relation. Mice with a single deleted Pten allele (Pten(+/-)) spontaneously develop complex atypical hyperplasia and ~20% develop endometrial cancer. To determine the effect of removing endogenous estrogen, we performed oophorectomies on Pten(+/-) mice. Although there was a reduction in the number and severity of hyperplastic lesions, the endometrial phenotype persisted, suggesting that Pten mutation, independent of estrogen, can initiate the development of complex atypical hyperplasia. To recapitulate the situation in women with unopposed estrogen, we implanted 17β-estradiol pellets in adult female Pten heterozygous mice, resulting in increased carcinoma incidence. Because studies have shown that estrogen largely acts on the endometrium via estrogen receptor ERα, we generated Pten(+/-)ERα(-/-) mice. Strikingly, 88.9% of Pten(+/-)ERα(-/-) mice developed endometrial hyperplasia/carcinoma. Furthermore, Pten(+/-)ERα(-/-) mice showed a higher incidence of in situ and invasive carcinoma, suggesting that endometrial tumorigenesis can progress in the absence of ERα. Thus, the relation between Pten alterations and estrogen signaling in the development of endometrial carcinoma is complex; the results presented herein have important implications for the treatment of endometrial hyperplasia and carcinoma in women.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Figures









Similar articles
-
Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice.Cancer Res. 2006 Apr 1;66(7):3375-80. doi: 10.1158/0008-5472.CAN-05-4019. Cancer Res. 2006. PMID: 16585156
-
Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.Pathol Res Pract. 2007;203(3):153-62. doi: 10.1016/j.prp.2007.01.003. Epub 2007 Feb 20. Pathol Res Pract. 2007. PMID: 17317031
-
Mutual contribution of Pten and estrogen to endometrial carcinogenesis in a PtenloxP/loxP mouse model.Int J Gynecol Cancer. 2011 Nov;21(8):1343-9. doi: 10.1097/IGC.0b013e31822d2a8a. Int J Gynecol Cancer. 2011. PMID: 21989218
-
[Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].Pathologe. 2011 Nov;32 Suppl 2:255-64. doi: 10.1007/s00292-011-1514-3. Pathologe. 2011. PMID: 22033684 Review. German.
-
Benign and Premalignant Lesions of the Endometrium.Surg Pathol Clin. 2019 Jun;12(2):315-328. doi: 10.1016/j.path.2019.01.003. Epub 2019 Apr 3. Surg Pathol Clin. 2019. PMID: 31097106 Review.
Cited by
-
Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome.EFSA J. 2023 Feb 14;21(2):e07744. doi: 10.2903/j.efsa.2023.7744. eCollection 2023 Feb. EFSA J. 2023. PMID: 36818642 Free PMC article.
-
Two-Way Development of the Genetic Model for Endometrial Tumorigenesis in Mice: Current and Future Perspectives.Front Genet. 2021 Dec 9;12:798628. doi: 10.3389/fgene.2021.798628. eCollection 2021. Front Genet. 2021. PMID: 34956336 Free PMC article. Review.
-
Estrogen affects the negative feedback loop of PTENP1-miR200c to inhibit PTEN expression in the development of endometrioid endometrial carcinoma.Cell Death Dis. 2018 Dec 18;10(1):4. doi: 10.1038/s41419-018-1207-4. Cell Death Dis. 2018. PMID: 30584245 Free PMC article.
-
ENDOMETRIAL CARCINOMA: THE INTERPLAY OF GENETICS AND HORMONES.Trans Am Clin Climatol Assoc. 2023;133:274-282. Trans Am Clin Climatol Assoc. 2023. PMID: 37701602 Free PMC article.
-
Steroid hormone intervenes in the endometrial tumorigenesis of pten ablation.J Cancer Prev. 2013 Dec;18(4):313-21. doi: 10.15430/jcp.2013.18.4.313. J Cancer Prev. 2013. PMID: 25337560 Free PMC article.
References
-
- Di Cristofano A., Ellenson L.H. Endometrial carcinoma. Annu Rev Pathol. 2007;2:57–85. - PubMed
-
- Risinger J.I., Hayes A.K., Berchuck A., Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736–4738. - PubMed
-
- Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., Li J., Parsons R., Ellenson L.H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935–3940. - PubMed
-
- Levine R.L., Cargile C.B., Blazes M.S., van Rees B., Kurman R.J., Ellenson L.H. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58:3254–3258. - PubMed
-
- Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., Berchuck A., Futreal P.A. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998;58:2500–2503. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials